Industry Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Outperform the Market" and is maintained [1] Core Insights - The retail pharmacy industry is undergoing accelerated consolidation, with a significant reduction in the number of stores, leading to increased concentration benefiting leading players [4][15] - The number of retail pharmacies in China has decreased by nearly 20,000 since the fourth quarter of 2024, with a net reduction of 8,800 stores in the third quarter of 2025 alone [15][21] - Leading pharmacies are expected to see profit margins improve in 2026 due to operational optimizations and cost control measures [5][21] - The innovation drug sector is currently in a correction phase, but the maturation of clinical data is expected to drive future market performance [7][25] - The medical device sector is showing signs of recovery, with leading companies reporting improved performance in the third quarter of 2025 [29][30] Summary by Sections Industry Overview - The closing index for the pharmaceutical and biotechnology sector is 8084.61, with a 52-week high of 9323.49 and a low of 6764.34 [1] Recent Market Performance - The A-share pharmaceutical and biotechnology sector fell by 2.06% in the last week of December 2025, underperforming the CSI 300 index by 1.47 percentage points [6][22] - The retail pharmacy sector experienced a decline of 4.11% during the same period [22] Retail Pharmacy Insights - The retail pharmacy industry is seeing a rapid exit of smaller players, with a focus on consolidating market share among leading pharmacies [15][37] - The implementation of drug traceability codes is expected to further increase industry concentration by raising operational costs for smaller pharmacies [20] Innovation Drug Sector - The innovation drug sector is experiencing a correction, but the maturation of clinical data is anticipated to be a key driver for future performance [7][25] - Companies with stable business development (BD) expectations are recommended for investment, including Innovent Biologics and 3SBio [26] Medical Device Sector - The medical device industry is expected to benefit from improved procurement processes and a reduction in the pressure from centralized procurement [29][30] - Leading companies are showing signs of recovery, with Q3 performance improving compared to earlier in the year [29] Traditional Chinese Medicine - The traditional Chinese medicine sector is under pressure but is expected to benefit from policies favoring essential medicines and inventory clearance [34][36]

Group 1 - The core viewpoint is that the pharmaceutical industry is expected to see moderate growth by 2025, driven by improved global liquidity and supportive national policies for industrial innovation [1][2] - The industry is entering a phase of high-quality growth, with significant reforms in the healthcare sector, including the establishment of a multi-faceted medical insurance payment system [1][2] - The focus is on long-term investment opportunities in innovative pharmaceutical companies, particularly in the medical device and traditional Chinese medicine sectors, as well as state-owned enterprises [1] Group 2 - The pharmaceutical manufacturing industry has experienced fluctuations in growth rates due to base effects and public health events, but it is expected to achieve moderate growth by 2025 as demand stabilizes and policy expectations become clearer [2] - The valuation of the pharmaceutical sector is currently at a historical low, with the latest valuation at the 27th percentile, indicating potential for recovery as institutional holdings remain below historical averages [3] - As of Q4 2024, public fund holdings in the pharmaceutical sector are at 8.18%, with a notable increase in holdings for certain innovative drug and CXO companies, suggesting a potential rise in investment in high-growth segments of the industry [3]